According to Franklin Covey's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.91529. At the end of 2024 the company had a P/S ratio of 1.82.
Year | P/S ratio | Change |
---|---|---|
2024 | 1.82 | -3.49% |
2023 | 1.89 | -27.5% |
2022 | 2.60 | -1.71% |
2021 | 2.65 | 61.85% |
2020 | 1.64 | -26.98% |
2019 | 2.24 | 46.67% |
2018 | 1.53 | 7.36% |
2017 | 1.42 | -2.99% |
2016 | 1.47 | 22.81% |
2015 | 1.20 | -21.35% |
2014 | 1.52 | -14.86% |
2013 | 1.79 | 39.19% |
2012 | 1.28 | 24.19% |
2011 | 1.03 | 8.93% |
2010 | 0.9480 | 30.23% |
2009 | 0.7279 | 89.99% |
2008 | 0.3831 | -21.83% |
2007 | 0.4901 | 18.1% |
2006 | 0.4150 | -14.78% |
2005 | 0.4870 | 229.25% |
2004 | 0.1479 | 44.15% |
2003 | 0.1026 | 0.66% |
2002 | 0.1019 | -60.26% |
2001 | 0.2565 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Spero Therapeutics SPRO | 0.7995 | -58.26% | ๐บ๐ธ USA |
Universal Technical Institute UTI | 1.18 | -38.48% | ๐บ๐ธ USA |